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Abstract
Background: Triple-negative breast cancer (TNBC) and basal-like breast cancer (BLBC) are breast cancer subtypes
with an especially poor prognosis. 8-Hydroxydeoxyguanosine (8-OHdG) is a widely used marker of oxidative stress
and the redox-state-regulating enzymes peroxiredoxins (PRDXs) are efficient at depressing excessive reactive
oxygen species. NF-E2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) are redox-sensitive
transcription factors that regulate PRDX expression. This is the first study to assess oxidative stress and or cell redox
state-regulating enzymes in TNBC and BLBC.
Methods: We assessed immunohistochemical expression of 8-OHdG, Nrf2, Keap1, PRDX III and PRDX IV in 79
women with invasive ductal breast carcinomas. Of these tumors, 37 represented TNBC (grade II-III tumors with total
lack of ER, PR and human epidermal growth factor receptor 2 [HER2] expression). Control cases (n = 42) were ER-
positive, PR-positive and HER2-negative. Of the 37 TNBCs, 31 had BLBC phenotype (TNBC with expression of
cytokeratin 5/6 or epidermal growth factor receptor 1).
Results: Patients with TNBC had worse breast cancer-specific survival (BCSS) than the control group (p = 0.015).
Expression of 8-OHdG was significantly lower in TNBC than in the non-TNBC group (p < 0.005). 8-OHdG
immunostaining was associated with better BCSS (p = 0.01), small tumor size (p < 0.0001) and low grade
(p < 0.0005). Keap1 overexpression was observed in the TNBC cohort (p = 0.001) and Keap1-positive patients had
worse BCSS than Keap1-negative women (p = 0.014). PRDX IV was overexpressed in the TNBC vs. the non-TNBC
group (p = 0.022).
Conclusions: Cellular redox state markers may be promising targets when elucidating the pathogenesis of TNBC.
Background
Breast cancers lacking both estrogen and progesterone
receptors (ER and PR), with simultaneous absence of
human epidermal growth factor 2 receptor (HER2) are
defined as triple-negative breast cancers (TNBCs). Cur-
rently there are no targeted therapies available for
TNBC and chemotherapy is the only option in both
adjuvant and metastatic settings. TNBC has a poor
prognosis in terms of disease-free survival and overall
survival and it tends to be associated with aggressive
and early recurrence [1]. Some TNBCs have a basal-like
phenotype, and these basal-like breast cancers (BLBCs)
show simultaneous expression of cytokeratin (CK) 5/6
or epidermal growth factor-1 (EGFR-1) [2]. It has been
suggested that BLBCs may have a different pathogenesis,
originating probably from mammary epithelial luminal
progenitor cells [3].
Reactive oxygen species (ROS) are continuously pro-
duced in all aerobic organisms as a consequence of aerobic
respiration. Although many ROS are vital regulators of sig-
naling pathways, oxidative stress occurs if ROS production
exceeds the capacity of the ROS-suppressing machinery,
which mainly consists of antioxidant enzymes. Oxidative
stress is a potent cause of damage in all cellular macromo-
lecules and it may also lead to carcinogenesis [4]. The
hydroxyl radical (￿OH) is the most unstable ROS and its
interaction with DNA leaves a specific and stable foot-
print, 8-hydroxydeoxyguanosine (8-OHdG i.e. 8-oxodG),
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chemistry, for example.
Peroxiredoxins (PRDXs) I-VI are one of the most
important antioxidant enzymes and they also modulate
intracellular signaling pathways related to apoptosis and
cell proliferation [5]. The main antioxidant function of
PRDXs is to reduce peroxides, including H2O2, to corre-
sponding alcohols and water. If H2O2 is not reduced
and it interacts with transition metals (usually ions of Fe
or Cu), ￿OH and consequently 8-OHdG can be formed.
PRDXs are strongly induced in oxidative conditions.
This induction is largely mediated by redox-sensitive
NF-E2-related factor 2 (Nrf2), which under oxidative
stress translocates to the nucleus and attaches to antiox-
idant response elements (AREs) of antioxidant genes,
thus stimulating synthesis of respective proteins [6-8].
Nrf2 is negatively regulated by another redox-sensitive
protein, Kelch-like ECH-associated protein 1 (Keap1).
Estrogens are important ROS inducers in ER-positive
breast cancer cells [9], although data from clinical series
is lacking. Our previous results have suggested that two
of the most important regulators of the cellular redox
state, PRDX III and PRDX IV, may have special roles in
steroid receptor-negative breast cancers [10]. This study
was designed to find out whether or not oxidative stress
and/or cell redox state-regulating enzymes have special
roles in TNBC and BLBC. These breast cancer subtypes
are especially aggressive and more accurate prognostic
and predictive biomarkers are urgently required.
Methods
The material consisted of 79 women with local or
locally advanced breast cancer from a prospective series
at Oulu University Hospital, Oulu, Finland, diagnosed
during 2000-2008. All tumors showed invasive ductal
histology. The specimens had been fixed in neutral for-
malin, embedded in paraffin blocks and stored at the
Department of Pathology at the same institute. The
patients were surgically staged according to the current
TNM classification system and the histological degree of
tumor differentiation was classified according to the
WHO Classification of Tumours [11]. The study was
approved by the Local Ethics Committee of the North-
ern Ostrobothnia Hospital District of Finland.
Immunohistochemistry and scoring
Paraffin-embedded tissues were first sectioned (4 μm
thickness) and placed on SuperFrostPlus glass slides,
f i x e da t3 7° Co v e r n i g h t ,a n dp r o c e s s e df u r t h e rw i t h i na
few days. The sections were deparaffinized in xylene and
then rehydrated in a descending ethanol series, incu-
bated in 10 mM citrate buffer (pH 6.0), boiled in a
microwave oven for 10 minutes, and cooled thoroughly
at room temperature before adding the primary anti-
b o d y .N e g a t i v ec o n t r o l sw e r ep r e p a r e db yu s i n gt h e
same procedure except that the primary antibodies were
replaced by PBS and serum isotype controls (Zymed
Laboratories, Inc.). Previously known positive control
samples were also used. Table 1 shows more details of
the staining for each antibody used.
Tumors exhibiting nuclear estrogen/progesterone
receptor expression in more than 10% of invasive tumor
cells were considered as steroid receptor-positive. The
TNBC group did not show any ER- or PR-positivity.
Membranous HER2 expression was also studied by
means of immunohistochemistry (IHC) and if a speci-
men exhibited a HER2-positive result (1+ to 3+ on a
scale of 0 to 3+) in IHC, Her2 gene amplification status
was determined by means of chromogenic in situ hybri-
dization (CISH). Breast cancers with six or more gene
copies of Her2 in cells were considered HER2-positive
[12]. Expression of Ki-67 was studied immunohisto-
chemically as described previously, the cut-off for nega-
tivity being <5% [10]. Cytokeratin 5/6 was scored
positive if any (weak or strong) cytoplasmic and/or
membranous invasive carcinoma cell staining was
observed and EGFR was scored positive if there were
more than 10% of positive cells.
When comparing PRDXs with each other or against
tumor parameters or survival, cytoplasmic PRDX
immunostaining was divided into two groups, as in our
previous breast cancer study [10]: 0 = absent or weak
staining and 1 = moderate or strong staining. Since
97.5% of the cases were negative or only weakly posi-
tive for nuclear PRDX III, this parameter was divided
into either negative or any amount of positive staining
for further statistical analyses. Interpretation of 8-
OHdG immunostaining was similar to that used for
cytoplasmic PRDXs, but only nuclear 8-OHdG staining
was evaluated. In the case of Nrf2, nuclear immunopo-
sitivity, and in the case of Keap1 both nuclear and
cytoplasmic immunopositivity were considered as a
positive result.
Immunostaining of 8-OHdG, Nrf2, Keap1, PRDX III
and PRDX IV was examined in three separate cohorts:
1) the whole study group; 2) triple-negative tumors; 3)
basal-like tumors. Tumors that did not express either
steroid receptors or HER2 and were grade II-III and
showed ductal histology were classified as triple-negative
carcinomas. To further identify the basal subtype among
these breast cancer specimens, expression of CK5/6 and
EGFR was determined in the triple-negative tumors.
Finally, the triple-negative tumors that also expressed
both EGFR and CK5/6 were classified as basal-like
breast cancers. The main patient and tumor characteris-
tics in each of these groups are shown in Table 2.
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SPSS 17.0.2 for Windows was applied for statistical ana-
lysis. The reported p-values are from 2-sided Pearson
chi-square tests, except for survival analysis. Survival
was analyzed by using Kaplan-Meier curves with the
log-rank test and only breast cancer-related death was
used as an endpoint. Cox regression analysis was used
in multivariate analysis. T-class was divided in statistical
analyses to either T1 or larger and grade was divided
into either grade I-II or grade III. Probability values
below 0.05 were considered significant.
Results
Thirty-seven of the 79 studied cases were classified as
TNBC. Of these 37 TNBCs, 31 (83.8%) exhibited the
BLBC phenotype, as they expressed either CK5/6 or
EGFR-1. The control cases (n = 42) expressed both ER
and PR and were HER2-negative. Primary tumor sizes
were larger in TNBC compared to non-TNBC group
(p = 0.013) and in BLBC compared to non-BLBC group
(p = 0.0054). Patients with TNBC had worse breast can-
cer-specific survival than the control group (p = 0.015)
(Figure 1). There was no difference in survival between
the BLBC and non-BLBC groups. The mean follow-up
time was 96.6 months.
Cytoplasmic PRDX III expression was observed in
68.4% of cases and nuclear PRDX III in 16.4%. PRDX IV
immunostaining was positive in 97.5% of cases and there
was virtually no nuclear PRDX IV expression. Nrf2 and
8-OHdG were located mainly in nuclei; Keap1 was
mainly cytoplasmic. Immunostaining expression patterns
in the subgroups are shown in detail in Table 3.
8-OHdG was overexpressed in the ER+/PR+/HER2-
group compared with TNBC samples (p = 0.0016) (Table
3). Keap1 immunostaining was more prevalent in the
TNBC group than in the control group (p = 0.0011). Cyto-
plasmic PRDX III showed a trend towards less frequent
expression in the TNBC cohort (p = 0.10). In addition, a
lack of nuclear PRDX III expression was more frequently
observed in the triple-negative carcinomas compared with
the ER+/PR+/HER2- control specimens (p = 0.060). On
the other hand, cytoplasmic PRDX IV was overexpressed
in the triple-negative breast carcinomas, compared with
the non-TNBC group (p = 0.022).
Immunostaining of Nrf2 and Keap1 showed significant
co-expression (p = 0.0037). Nrf2 and PRDX III were sig-
nificantly co-expressed when all cases were considered
(p = 0.008) and also in non-TNBC-cases (p = 0.011),
but not in the TNBC group alone (p = 0.201). PRDX III
expression in nuclei was independent of its presence in
cytoplasm. PRDX IV expression was not significantly
associated with PRDX III expression (p = 0.068 for
expression in the same samples). Expression of 8-OHdG
was not associated with antioxidant enzymes when all
samples were considered. However, 8-OHdG expression
had a significant association with low cytoplasmic
PRDX III expression in TNBC cases (p = 0.018), but in
Table 1 Immunohistochemical methods used in this study
Antibody (Clone/Product code) Dilution Immunostaining method Source of primary antibody
CK5/6 (D5/16 B4) 1:200 Dako Envision Kit DakoCytomation, Glostrup, Denmark
EGFR (NCL-L-EGFR-384) 1:200 Dako Envision Kit Leica Biosystems, Newcastle, United Kingdom
ER (NCL-ER-6F11) 1:50 Dako Envision Kit Novocastra, Newcastle upon Tyne, United Kingdom
HER2 (NCL-CB11) 1:500 Dako Envision Kit Novocastra
PR (PgR 636) 1:150 Dako Envision Kit DakoCytomation
PRDX III (LF-P A 0030) 1:500 Histostain-Plus Bulk Kit Labfrontier, York, United Kingdom
PRDX IV (LF-P A 0009) 1:500 Histostain-Plus Bulk Kit Labfrontier
8-OHdG (N45.1) 1:50 Dako Envision Kit JaICA, Fukuroi, Japan
Nrf2 (SC-722) 1:100 Histostain Plus Broad Spectrum Kit Santa Cruz Biotechnology, Santa Cruz, USA
Keap1 (SC-15246) 1:100 Biocare Medical HRP Polymer Kit Santa Cruz
Table 2 Patient and tumor characteristics
Triple-
negative
ER+/PR
+/HER2-
Basal-like Total
T
1 11 (29.7%) 25 (59.5%) 6 (19.4%) 36 (45.6%)
2 23 (62.2%) 14 (33.3%) 22 (71.0%) 37 (46.8%)
3+4 3 (8.1%) 3 (7.2%) 3 (9.7%) 6 (7.6%)
Nodal status
Negative 21 (56.8%) 23 (54.8%) 18 (58.1%) 44 (55.7%)
Positive 16 (43.2%) 19 (45.2%) 13 (41.9%) 35 (44.3%)
Ki-67
Negative 3 (8.1%) 7 (16.7%) 2 (6.5%) 10 (12.7%)
Positive 34 (91.9%) 35 (83.3%) 29 (93.5%) 69 (87.3%)
Grade
I 0 (0.0%) 8 (19.0%) 0 (0.0%) 8 (10.1%)
II 2 (5.4%) 27 (64.3%) 1 (3.2%) 29 (36.7%)
III 35 (94.6%) 7 (16.7%) 30 (96.8%) 42 (53.2%)
The basal-like cohort is part of the triple-negative cohort.
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sence of cytoplasmic PRDX III expression (p = 0.028).
8-OHdG immunostaining was associated highly signif-
icantly with the traditional factors of good prognosis
(low grade p = 0.00020, low T-class p = 0.00065). Keap1
was overexpressed in grade III tumors (p = 0.0058) and
near-significantly in high Ki-67 tumors (p = 0.075).
Nuclear PRDX III expression was associated with less
aggressive tumor characteristics, since it was overex-
pressed within the T1 tumor population (p = 0.011) and
in grade I-II disease (p = 0.029).
8-OHdG-positive immunostaining was associated with
better breast cancer-specific survival (BCSS) when all
patients were taken into account (p = 0.01). Keap1-posi-
tive patients had shorter BCSS than those with Keap1-
negative tumors (p = 0.014). Cytoplasmic PRDX III
immunostaining had a nearly significant association with
poorer BCSS (p = 0.06). In multivariate analysis none of
the studied markers were independent from traditional
prognostic factors.
Discussion
There is great variability in the reported frequencies of
triple-negative and basal-like breast cancers in the litera-
ture, depending on the criter i au s e d .T h ep r e v a l e n c eo f
TNBC has ranged from 17.1% to 30.5% and that of BLBC
from 8.0% to 55.7% [13]. Here we reassessed the steroid
receptor status and HER2 status of tumors; those tumors
without any ER and PR immunostaining were considered
as receptor negative and tumors exhibiting more than
10% of invasive tumor cells were considered as steroid
receptor-positive. In addition, only grade II-III tumors
with ductal histology were included in the TNBC cohort.
It is also known that triple-negative and basal-like sub-
types of breast carcinoma are not single cohesive entities
but instead reflect a collection of different diseases. Out-
come in cases of TNBC has consistently been worse
compared with ER- and PR-positive tumors, which was
again confirmed in the current material. TNBC and
BLBC tumors are usually larger and of higher grade com-
pared with receptor-positive breast cancer tumors and
some reports suggest that cases of BLBC are more often
node-negative [3,14-16]. In the current study, triple-
negative carcinomas were larger than ER+/PR+/HER2-
cancers, as were basal-like carcinomas compared to non-
basal-like triple-negative breast cancers, but no associa-
tion with nodal status was observed. The proportion of
basal-like subtype showing cancers in our material is in
line with previous reports [16].
One of the most important estrogen-related carcino-
genic mechanisms is oxidative metabolism of estrogen
and subsequent formation of ROS [17,18]. Published data
from several laboratories suggest that in vitro, physiologi-
cal estrogen concentrations induce significant oxidative
stress and that estrogen-induced ROS formation takes
place in mitochondria in particular [19,20]. Other studies
have provided evidence that 8-OHdG levels in the ER-
positive MCF-7 breast cancer cell line are over 9-fold
higher than in triple-negative MDA-MB-231 cells [9] and
inhibition of estrogen receptor alpha expression signifi-
cantly reduces estrogen-induced 8-OHdG formation in
MCF-7 cells [21]. Since estrogen levels in ER-positive
Figure 1 Kaplan-Meier curves showing breast cancer-specific
survival in different subgroups. TNBC patients have significantly
shorter survival compared the control group (p = 0.015) (A). Women
with 8-OHdG-positive tumors have better breast cancer-specific
survival when all patients are taken into account (p = 0.011) (B).
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finding that 8-OHdG (as a marker of ROS-derived DNA
damage) was highly overexpressed in the ER+/PR
+/HER2- group (73.2%) compared with TNBCs (37.1%)
is in line with the above data. Previous and current data
taken together suggest that ROS play a major role in ster-
oid receptor-positive breast cancer pathogenesis in parti-
cular, but not necessarily in cases of TNBC (including
BLBC).
A negative prognostic value of immunohistochemical
8-OHdG expression has been reported in connection
with at least colorectal carcinoma [23], ovarian cancer
[24] and malignant melanoma [25]. Nevertheless, there
i sag r o w i n gb o d yo fe v i d e n c et h a ti nb r e a s tc a n c e rt h e
prognostic value of 8-OHdG is different. We have
recently reported that immunohistochemical 8-OHdG
expression is an independent factor related to good
prognosis in breast cancer, especially as regards ductal
histology [26]. In another previous study we found that
8-OHdG expression was significantly diminished in
invasive breast carcinomas compared with non-invasive
breast lesions [27]. The current data confirm previous
results, as 8-OHdG was a marker of good BCSS also in
the current population.
When cells are exposed to oxidative stress, Keap1
undergoes a modification that allows Nrf2 to be released
from a complex with it and translocate to the nucleus
where it binds to antioxidant response elements of DNA
[8]. Nrf2-mediated antioxidant enzyme induction is one
of the major defense mechanisms against excessive ROS
production and, on the other hand, PRDX enzymes are
considered to be among the most efficient cell redox
state-regulating enzymes [8,28]. The importance of
PRDXs is derived partly from their wide subcellular dis-
tribution, in contrast to most other antioxidant enzymes.
T h em a j o r i t yo fR O Sa r ep r o d u c e di nm i t o c h o n d r i a
under physiological conditions and PRDX III is an espe-
c i a l l yi m p o r t a n tp a r to fa n t i o x i d a n td e f e n s e ,s i n c ei ti s
located mainly in mitochondria. Peroxiredoxin IV is
found in lysosomes, peroxisomes and the endoplasmic
reticulum, where oxidative stress is also a potent threat
[5]. Previous studies carried out in vitro have
demonstrated induction of PRDXs via the Nrf2/Keap1
pathway [28], but there are no reports on Nrf2 or Keap1
in clinical breast cancer material. The current data is in
line with previous in vitro r e s u l t sa sr e g a r d ss t e r o i d
receptor-positive breast cancer, since there was highly
significant co-expression of PRDX III and Nrf2 in ER
+/PR+/HER2- cases, which may reflect Nrf2-mediated
PRDX induction after estrogen-induced oxidative stress.
Furthermore, PRDX III was associated with 8-OHdG
expression in the non-TNBC cohort, probably represent-
ing antioxidant induction as a response to oxidative
imbalance. Keap1 was highly overexpressed in the TNBC
group compared with the steroid receptor-positive con-
trol group, which implies that there is no need for inten-
sive (Nrf2-mediated) free radical scavenging in cases of
TNBC as a result of a lack of estrogen-induced oxidative
stress. Keap1-positive tumors were more aggressive than
Keap1-negative ones and Keap1 expression associated
also to poor prognosis. This probably derives from the
sensitive induction of Keap1 in stressed and damaged
tumors, rather than carcinogenesis promoting features of
Keap1 itself. However, further mechanistic investigations
are required to confirm these hypotheses.
In a previous tissue microarray study we reported on
PRDX III overexpression in ER- and PR-positive breast
cancers and PRDX IV in PR-positive cases [10]. In that
study, with unselected breast cancer cases and with
older methods of steroid receptor assessment, PRDX III-
and PRDX IV-positive cases were associated with better
prognosis. In the current material neither of the studied
PRDX enzymes showed significant association with sur-
vival. We observed PRDX IV overexpression in TNBC,
especially in non-basal-like breast cancers. PRDX III
expression was similar in the TNBC and non-TNBC
groups, but PRDX III-positive tumors tended to be
smaller and of lower grade. This association with lower
grade was observed in a previous study [10] and sug-
gests a protective role of this mitochondrial enzyme in
breast carcinogenesis. All in all, PRDXs III and IV could
function as protective enzymes in ER- and PR-positive
breast carcinomas, working against the ROS induction
of estrogen metabolites.
Table 3 Number of positive immunostaining results in different subgroups and corresponding p-values
Triple-negative ER+/PR+/HER2- p-value Basal-like Non-basal-like p-value
Cytoplasmic PRDX III 3 (8.1%) 9 (21.4%) 0.10 2 (6.5%) 1 (16.7%) 0.42
Nuclear PRDX III 3 (8.1%) 10 (23.8%) 0.060 3 (9.7%) 0 (0.0%) 0.43
Cytoplasmic PRDX IV 27 (73.0%) 20 (47.6%) 0.022 22 (71.0%) 5 (83.3%) 0.53
8-OHdG 13 (37.1%) 30 (73.2%) 0.0016 10 (33.3%) 3 (60.0%) 0.25
Nrf2 12 (33.3%) 11 (26.8%) 0.53 10 (33.3%) 2 (33.3%) 1.0
Keap1 26 (76.5%) 16 (39.0%) 0.0011 22 (78.6%) 4 (66.7%) 0.53
Criteria for positive immunostaining for each antibody are described in the Materials and Methods section.
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To summarize, the current results, together with pre-
vious preclinical observations, suggest that estrogen
induces significant oxidative stress in ER+/PR+ breast
cancer compared with TNBC. The Nrf2/Keap1 pathway
is more active in steroid receptor-positive disease and
this subsequently causes induction of antioxidant
defense that is not observed in TNBC. Further studies
with larger patient groups are required to elucidate pos-
sible prognostic roles of the studied factors.
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